AbClon Inc. (KOSDAQ:174900)

Market Cap	1.09T
Revenue (ttm)	3.80B
Net Income (ttm)	-16.23B
Shares Out	19.73M
EPS (ttm)	-895.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,122
Average Volume	386,571
Open	57,600
Previous Close	57,600
Day's Range	54,800 - 57,900
52-Week Range	6,810 - 59,500
Beta	0.91
RSI	63.89
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.42 billion, 27.2% more than in 2023.